We explored the variations of blood biomarkers of Alzheimer’s disease (AD) by chronic diseases and systemic inflammation.
We explored the association of AD blood biomarkers with chronic diseases and systemic inflammation (interleukin-6 [IL-6]), in 2366 dementia-free participants of the Swedish National Study on Aging and Care-in Kungsholmen, using quantile regression models.
A greater number of co-occurring chronic diseases was associated with higher concentrations of phosphorylated-tau 181 (p-tau181), total-tau (t-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) (p < 0.01). Anemia, kidney, cerebrovascular, and heart diseases were associated with variations in the levels of AD blood biomarkers. Participants in the highest (vs. lowest) interleukin-6 (IL-6) tertile had higher NfL concentration. Systemic inflammation amplified the associations between several chronic diseases and p-tau181, t-tau, NfL, and GFAP.
In the community, the concentration of AD blood biomarkers varies in relation to medical conditions and systemic inflammation. Recognizing these influences is crucial for the accurate interpretation and clinical implementation of blood biomarkers.

Participants with a complex clinical profile (i.e., multiple co-occurring diseases or specific disease combinations) display elevated levels of AD blood-biomarkers.
Anemia, heart, cerebrovascular, and kidney diseases are associated with variations is the levels of AD blood biomarkers in cognitively intact older adults.
Systemic inflammation amplifies the association between several chronic diseases and AD blood biomarkers.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Martina Valletta,
Davide Liborio Vetrano,
Debora Rizzuto,
Bengt Winblad,
Marco Canevelli,
Sarah Andersson,
Matilda Dale,
Claudia Fredolini,
Laura Fratiglioni,
Giulia Grande | May 9, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents